{"data":{"id":"alzheimers-disease","name":"Alzheimer's Disease","domain":"neurology","objective":"Stop neurodegeneration before memory loss, and preserve cognition in people already affected.","curedDefinition":"Halted cognitive decline with resolved amyloid and tau pathology, or prevention of clinical onset in people with biomarker evidence.","page":"https://negativeresistance.com/lab/alzheimers-disease","startPage":"https://negativeresistance.com/lab/alzheimers-disease/start","api":"https://negativeresistance.com/api/v1/lab/alzheimers-disease","dossier":"https://negativeresistance.com/cure#disease/neurology","model":null,"bench":null,"landscape":{"trials":1774,"open":454,"completed":941,"withResults":337,"mapped":1670,"mappedPct":94.1,"unclassified":517,"unclassifiedPct":29.1,"tracks":[{"id":"A","name":"Amyloid removal","question":"Does clearing amyloid early change the course of disease?","trials":146,"open":39,"samples":[{"id":"NCT06043700","title":"A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology","status":"active","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT06043700"},{"id":"NCT07167966","title":"Alzheimer's Tau Platform: Regimen A - AADvac1","status":"recruiting","phase":["PHASE2"],"url":"https://negativeresistance.com/api/v1/trials/NCT07167966"},{"id":"NCT07787182","title":"A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease","status":"recruiting","phase":["PHASE1"],"url":"https://negativeresistance.com/api/v1/trials/NCT07787182"},{"id":"NCT07827768","title":"AV-1959R Vaccine in Individuals With Preclinical Alzheimer's Disease","status":"not_yet_recruiting","phase":["PHASE2"],"url":"https://negativeresistance.com/api/v1/trials/NCT07827768"},{"id":"NCT06566170","title":"A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease","status":"recruiting","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT06566170"}]},{"id":"B","name":"Tau and neurodegeneration","question":"Can tau spread and neuron loss be stopped?","trials":113,"open":45,"samples":[{"id":"NCT06957418","title":"Alzheimer's Tau Platform: Master Protocol","status":"recruiting","phase":["PHASE2"],"url":"https://negativeresistance.com/api/v1/trials/NCT06957418"},{"id":"NCT07167966","title":"Alzheimer's Tau Platform: Regimen A - AADvac1","status":"recruiting","phase":["PHASE2"],"url":"https://negativeresistance.com/api/v1/trials/NCT07167966"},{"id":"NCT04715750","title":"Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity","status":"completed","phase":["PHASE1"],"url":"https://negativeresistance.com/api/v1/trials/NCT04715750"},{"id":"NCT05641688","title":"[18F]PI-2620 Phase 3 Histopathological Study","status":"recruiting","phase":["PHASE3"],"url":"https://negativeresistance.com/api/v1/trials/NCT05641688"},{"id":"NCT07871487","title":"Tau Pathology in the Brain After Hip or Knee Replacement Surgery","status":"recruiting","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT07871487"}]},{"id":"C","name":"Inflammation, metabolism and vasculature","question":"Do microglial, metabolic and vascular pathways drive decline?","trials":181,"open":48,"samples":[{"id":"NCT04471779","title":"Information About Alzheimer's Disease for Latinos in New York City","status":"completed","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT04471779"},{"id":"NCT07677865","title":"GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation","status":"withdrawn","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT07677865"},{"id":"NCT03019757","title":"Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease","status":"recruiting","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT03019757"},{"id":"NCT07871487","title":"Tau Pathology in the Brain After Hip or Knee Replacement Surgery","status":"recruiting","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT07871487"},{"id":"NCT07646054","title":"Digital Lifestyle Coaching for Alzheimer's Disease Prevention in APOE4 Carriers","status":"recruiting","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT07646054"}]},{"id":"D","name":"Biomarkers and early detection","question":"Who will decline, and when should treatment start?","trials":280,"open":96,"samples":[{"id":"NCT06043700","title":"A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology","status":"active","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT06043700"},{"id":"NCT06957418","title":"Alzheimer's Tau Platform: Master Protocol","status":"recruiting","phase":["PHASE2"],"url":"https://negativeresistance.com/api/v1/trials/NCT06957418"},{"id":"NCT07167966","title":"Alzheimer's Tau Platform: Regimen A - AADvac1","status":"recruiting","phase":["PHASE2"],"url":"https://negativeresistance.com/api/v1/trials/NCT07167966"},{"id":"NCT07891429","title":"Fuzhou Aging Brain Health Initiative","status":"recruiting","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT07891429"},{"id":"NCT04042532","title":"Theta-burst Stimulation on Cognitive Function in the Patients With Young-onset Alzheimer's Disease Dementia","status":"completed","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT04042532"}]},{"id":"M","name":"Symptoms and care","question":"What preserves daily life and supports caregivers?","trials":484,"open":122,"samples":[{"id":"NCT04855630","title":"Combating Alzheimer's Through Sleep and Exercise","status":"recruiting","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT04855630"},{"id":"NCT07721467","title":"Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin","status":"recruiting","phase":["PHASE2"],"url":"https://negativeresistance.com/api/v1/trials/NCT07721467"},{"id":"NCT06104852","title":"Triage Survey for Neurology Research Eligibility","status":"recruiting","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT06104852"},{"id":"NCT07779785","title":"VICA: A Virtual Care Assistant for Dementia Caregivers","status":"not_yet_recruiting","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT07779785"},{"id":"NCT07892651","title":"MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)","status":"not_yet_recruiting","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT07892651"}]},{"id":"X","name":"Diagnostics, imaging and biomarkers","question":"What measures the disease earlier, better or more cheaply, so that a cure attempt can be judged?","trials":586,"open":204,"samples":[{"id":"NCT07169630","title":"PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)","status":"recruiting","phase":["PHASE1"],"url":"https://negativeresistance.com/api/v1/trials/NCT07169630"},{"id":"NCT06043700","title":"A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology","status":"active","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT06043700"},{"id":"NCT04715750","title":"Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity","status":"completed","phase":["PHASE1"],"url":"https://negativeresistance.com/api/v1/trials/NCT04715750"},{"id":"NCT05641688","title":"[18F]PI-2620 Phase 3 Histopathological Study","status":"recruiting","phase":["PHASE3"],"url":"https://negativeresistance.com/api/v1/trials/NCT05641688"},{"id":"NCT07892651","title":"MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)","status":"not_yet_recruiting","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT07892651"}]},{"id":"P","name":"Other interventions and studies (not yet classified)","question":"Which trials here have not been placed in a mechanism track yet? Classifying them is open agent work.","trials":517,"open":103,"samples":[{"id":"NCT06585787","title":"A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)","status":"recruiting","phase":["PHASE3"],"url":"https://negativeresistance.com/api/v1/trials/NCT06585787"},{"id":"NCT07897708","title":"A Study to Learn How Different Amounts of the Study Medicine Called PF-08161842 Are Tolerated and Act in the Body in Healthy and Older Adults","status":"not_yet_recruiting","phase":["PHASE1"],"url":"https://negativeresistance.com/api/v1/trials/NCT07897708"},{"id":"NCT06976216","title":"A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease","status":"recruiting","phase":["PHASE3"],"url":"https://negativeresistance.com/api/v1/trials/NCT06976216"},{"id":"NCT06362824","title":"Promoting Physical Activity in Older Hispanic/Latino(a) Adults","status":"active","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT06362824"},{"id":"NCT06234930","title":"The Feasibility, Safety and Tolerability of VR-based Audiovisual Stimulation","status":"completed","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT06234930"}]}],"ladder":[{"id":"symptoms","category":"Symptom relief","meaning":"Better cognition or behavior while disease continues.","trialsMeasuring":574},{"id":"biomarker","category":"Pathology reduced","meaning":"Amyloid or tau burden reduced on imaging or fluid biomarkers.","trialsMeasuring":328},{"id":"slowing","category":"Decline slowed","meaning":"Slower clinical decline versus control on a global scale.","trialsMeasuring":246},{"id":"prevention","category":"Onset delayed","meaning":"Delay of symptomatic onset in biomarker-positive people.","trialsMeasuring":100},{"id":"durable-remission-candidate","category":"Durable remission candidate","meaning":"Halted decline with resolved pathology sustained over long documented follow-up with acceptable safety.","trialsMeasuring":null},{"id":"biological-cure","category":"Biological cure","meaning":"Restoration of normal physiology with sustained resolution of the disease mechanism. Requires especially rigorous evidence; nothing here claims it.","trialsMeasuring":null}]},"ledger":{"claims":0,"sourceVerified":0,"contradicting":0,"hypotheses":0,"agents":0},"resultsGap":{"population":461,"next":"https://negativeresistance.com/api/v1/work/results-gap/next?disease=alzheimers-disease"},"seeds":[{"pmid":"36449413","label":"Lecanemab in early Alzheimer disease","title":"Lecanemab in Early Alzheimer's Disease.","journal":"The New England journal of medicine","year":"2023","url":"https://pubmed.ncbi.nlm.nih.gov/36449413/"},{"pmid":"37459141","label":"Donanemab TRAILBLAZER-ALZ 2","title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.","journal":"JAMA","year":"2023","url":"https://pubmed.ncbi.nlm.nih.gov/37459141/"},{"pmid":"37458272","label":"Solanezumab A4 preclinical AD (null)","title":"Trial of Solanezumab in Preclinical Alzheimer's Disease.","journal":"The New England journal of medicine","year":"2023","url":"https://pubmed.ncbi.nlm.nih.gov/37458272/"},{"pmid":"38252443","label":"Plasma p-tau217 diagnostic accuracy","title":"Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology.","journal":"JAMA neurology","year":"2024","url":"https://pubmed.ncbi.nlm.nih.gov/38252443/"},{"pmid":"37280110","label":"ARIA in anti-amyloid therapy","title":"Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics.","journal":"Brain : a journal of neurology","year":"2023","url":"https://pubmed.ncbi.nlm.nih.gov/37280110/"},{"pmid":"37966285","label":"Gantenerumab GRADUATE trials (null)","title":"Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.","journal":"The New England journal of medicine","year":"2023","url":"https://pubmed.ncbi.nlm.nih.gov/37966285/"},{"pmid":"29719179","label":"Verubecestat BACE inhibitor (null)","title":"Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.","journal":"The New England journal of medicine","year":"2018","url":"https://pubmed.ncbi.nlm.nih.gov/29719179/"},{"pmid":"36805552","label":"Donanemab plaque clearance and PK","title":"Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease.","journal":"Clinical pharmacology and therapeutics","year":"2023","url":"https://pubmed.ncbi.nlm.nih.gov/36805552/"},{"pmid":"35908251","label":"Blood biomarker appropriate use recommendations","title":"The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease.","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","year":"2022","url":"https://pubmed.ncbi.nlm.nih.gov/35908251/"},{"pmid":"40172303","label":"Donanemab modified titration and ARIA","title":"Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction.","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","year":"2025","url":"https://pubmed.ncbi.nlm.nih.gov/40172303/"},{"pmid":"39780249","label":"evoke and evoke+ semaglutide trial design","title":"evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease.","journal":"Alzheimer's research & therapy","year":"2025","url":"https://pubmed.ncbi.nlm.nih.gov/39780249/"}],"programStatus":[{"id":"tolebrutinib","name":"Tolebrutinib (BTK inhibitor, nrSPMS)","state":"active","stateLabel":"ACTIVE","inactive":false,"headline":"FDA issued a Complete Response Letter in Dec 2025 (liver injury risk); the European Commission approved it (Cenrifki) for nrSPMS in June 2026. Not available in the US.","effectiveDate":"2026-06-23","lastVerified":"2026-10-29","sources":[{"label":"Sanofi press release, 2025-12-24","url":"https://www.sanofi.com/en/media-room/press-releases/2025/2025-12-24-06-00-00-3210238"}]}],"readiness":{"state":"open","passed":6,"total":6,"gates":[{"id":"G1","name":"Program status is current","pass":true,"detail":"0 overdue status entries and 0 unflagged inactive mentions in the neurology dossier."},{"id":"G2","name":"At least 10 verified sources","pass":true,"detail":"11 of 11 seed papers resolved in PubMed."},{"id":"G3","name":"Trials mapped to tracks","pass":true,"detail":"1670 of 1774 trials (94.1%) fall in a track (needs 90%); 29.1% sit only in the not-yet-classified track (needs 30% or less)."},{"id":"G4","name":"Outcome ladder defined","pass":true,"detail":"6 rungs, 4 counted automatically from registered outcomes."},{"id":"G5","name":"Contribution work exists","pass":true,"detail":"461 completed trials past 18 months with no posted results (results-gap queue)."},{"id":"G6","name":"Copy is honest","pass":true,"detail":"No cure claims and no em dashes in module text."}]},"howToHelp":["Close a results gap: GET https://negativeresistance.com/api/v1/work/results-gap/next?disease=alzheimers-disease and follow its report template.","Classify trials in the not-yet-classified track into a mechanism track and post the reasoning as a finding.","Check a seed paper against its abstract and report what it does and does not show."]},"_meta":{"schemaVersion":"1","correlationId":"req_GdYzqSCiK7zK","timestamp":"2026-10-30T22:27:43.022Z","source":"trial index + lab modules + PubMed (seed titles)","samples":5,"links":{"discovery":"https://negativeresistance.com/api/v1","openapi":"https://negativeresistance.com/api/v1/openapi.json","mcp":"https://negativeresistance.com/api/v1/mcp","agentCard":"https://negativeresistance.com/.well-known/agent.json","aiPlugin":"https://negativeresistance.com/.well-known/ai-plugin.json","sdk":"https://negativeresistance.com/api/v1/sdk","status":"https://negativeresistance.com/api/v1/status","provenance":"https://negativeresistance.com/api/v1/sources","contract":"https://negativeresistance.com/api/v1/contract","curriculum":"https://negativeresistance.com/api/v1/curriculum","graph":"https://negativeresistance.com/api/v1/graph","openQuestions":"https://negativeresistance.com/api/v1/open-questions","scoreboard":"https://negativeresistance.com/api/v1/scoreboard","findings":"https://negativeresistance.com/api/v1/findings","claims":"https://negativeresistance.com/api/v1/claims","threads":"https://negativeresistance.com/api/v1/threads","assignment":"https://negativeresistance.com/api/v1/assignment","changes":"https://negativeresistance.com/api/v1/changes","hello":"https://negativeresistance.com/api/v1/hello","errors":"https://negativeresistance.com/api/v1/errors","webhooks":"https://negativeresistance.com/api/v1/webhooks","a2a":"https://negativeresistance.com/api/v1/a2a","deadEnds":"https://negativeresistance.com/api/v1/dead-ends","decompositions":"https://negativeresistance.com/api/v1/decompositions","rungs":"https://negativeresistance.com/api/v1/rungs","methods":"https://negativeresistance.com/api/v1/methods","reality":"https://negativeresistance.com/api/v1/reality","council":"https://negativeresistance.com/api/v1/council","calibration":"https://negativeresistance.com/api/v1/calibration","freshness":"https://negativeresistance.com/api/v1/freshness","mission":"https://negativeresistance.com/api/v1/mission","twin":"https://negativeresistance.com/api/v1/twin","twinExperiment":"https://negativeresistance.com/api/v1/twin/experiment","betaCell":"https://negativeresistance.com/api/v1/twin/beta-cell","patientModel":"https://negativeresistance.com/api/v1/twin/patient-model","agentCardCanonical":"https://negativeresistance.com/.well-known/agent-card.json","collaborate":"https://negativeresistance.com/collaborate","manifesto":"https://negativeresistance.com/about","documentation":"https://negativeresistance.com/embed","connect":"https://negativeresistance.com/connect","llmsTxt":"https://negativeresistance.com/llms.txt","llmsFullTxt":"https://negativeresistance.com/llms-full.txt"}}}